^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | berzosertib (M6620) (ATR inhibitor) + orludodstat (BAY2402234) (DHODH inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4189 TP53 Aberrant B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Are Uniquely Sensitive to a Combination of Pyrimidine De Novo Synthesis Blockade and Replication Checkpoint Inhibition
Published date:
11/02/2023
Excerpt:
Preliminary results from in vivo experiments using p53 deficient patient derived xenografts indicate that the combination of Orludodstat and Berzosertib is well tolerated, while significantly delaying leukemic growth (Figure 1 B).
